These findings suggest that Th17 cells play an important role in the pathogenesis of early phase RA, indicating the usefulness of anti-IL-17 antibodies in the early phase of RA but not in the late phase of RA or in patients resistant to other biologics such as anti-TNF antibodies. The gene discussed is IL17A; the disease is rheumatoid arthritis.